{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"30.4","value":"12.8"},{"groupId":"OG001","lowerLimit":"11.9","upperLimit":"22.9","value":"17.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Overall survival for all will be the number of months from study entry to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28","id":"OG000","title":"DL1 - 3mg Lxazomib"},{"description":"Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28","id":"OG001","title":"DL2 - 4mg Lxazomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 3 years from start of treatment","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}